<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5622da2f-c152-42a3-87d2-cf6311562a93"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use NEVANAC<sup>*</sup> safely and effectively. See full prescribing information for NEVANAC.</content>
      <br/>
      <content styleCode="bold">NEVANAC (nepafenac ophthalmic suspension) 0.1%, for topical ophthalmic use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 2005</content>
      <br/>
   </title>
   <effectiveTime value="20201002"/>
   <setId root="3ad48650-75e3-4c74-9302-01b0088f164e"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="008018525" root="1.3.6.1.4.1.519.1"/>
            <name>Alcon Laboratories, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <relatedDocument typeCode="RPLC">
      <relatedDocument>
         <id root="80a2f7a6-5b85-813d-eb99-3b8e669328c8"/>
         <setId root="4c9ae54a-97a0-4613-a092-31e86d9bfc91"/>
         <versionNumber value="1"/>
      </relatedDocument>
   </relatedDocument>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="ac5bb5f6-c2c5-40ef-b261-707ceb4ef225"/>
               <code code="48780-1" displayName="SPL LISTING DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20171215"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0065-0002" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>NEVANAC</name>
                        <formCode code="C60995" displayName="SUSPENSION/ DROPS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>nepafenac</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0J9L7J6V8C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NEPAFENAC</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0J9L7J6V8C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NEPAFENAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="HHT01ZNK31" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Y27PUL9H56" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TYLOXAPOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="3"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0065-0002-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20050906"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021862" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20050906"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" displayName="OPHTHALMIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="_1_INDICATIONS_AND">
               <id root="9b5e6fc4-6ec5-4246-b106-e98b7bbd4e68"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
                  <content styleCode="bold">
		     
	INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>NEVANAC<sup>*</sup> 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery.</paragraph>
               </text>
               <effectiveTime value="20190131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>NEVANAC 0.1%, is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_2_DOSAGE_AND">
               <id root="f30dbae9-744a-4e68-804b-497da85c844b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2</content>
		     
	<content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <effectiveTime value="20190131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>One drop of NEVANAC 0.1% should be applied to the affected eye three times daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="47feb512-98cb-4ed8-a947-e8ab6fd5c7ac"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1
		     
	Recommended Dosing</title>
                     <text>
                        <paragraph>One drop of NEVANAC 0.1% should be applied to the affected eye three times daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. Shake the container well prior to dosing.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="34f24c15-f53f-403b-9919-fa6f4e32066b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2
		     
	Use with Other Topical Ophthalmic Medications</title>
                     <text>
                        <paragraph>NEVANAC 0.1% may be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.</paragraph>
                        <paragraph>If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart. </paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3_DOSAGE_FORMS">
               <id root="1366795f-f3f0-4208-b5bb-0dca6adc2a82"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3</content>
                  <content styleCode="bold">
		     
	DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Sterile ophthalmic suspension 0.1%</paragraph>
                  <paragraph>3 mL in a 4 mL bottle</paragraph>
               </text>
               <effectiveTime value="20170622"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Sterile ophthalmic suspension: 0.1% (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)<br/>3 mL in a 4 mL bottle.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_4_CONTRAINDICATIONS">
               <id root="456c2f3f-40a6-4752-bd0c-fc31aa4657bd"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4</content>
                  <content styleCode="bold">
		     
	CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>NEVANAC 0.1% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDs).</paragraph>
               </text>
               <effectiveTime value="20190131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDS).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="02a89b5a-b89b-49fe-9812-16b7c1a93259"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5</content>
                  <content styleCode="bold">
		     
	WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20190131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Increased bleeding time due to interference with thrombocyte aggregation (<linkHtml href="#_5_1_Increased_Bleeding">5.1</linkHtml>)</item>
                           <item>Delayed healing (<linkHtml href="#_5_2_Delayed_Healing">5.2</linkHtml>)</item>
                           <item>Corneal effects including keratitis (<linkHtml href="#_5_3_Corneal_Effects">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Increased_Bleeding">
                     <id root="198544e9-a2cc-406a-881d-7462a3c21dc0"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1
		     
	Increased Bleeding Time</title>
                     <text>
                        <paragraph>With some NSAIDs, including NEVANAC 0.1%, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery.</paragraph>
                        <paragraph>It is recommended that NEVANAC 0.1% be used with caution in patients with known bleeding tendencies, or who are receiving other medications, which may prolong bleeding time.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2_Delayed_Healing">
                     <id root="c7407574-850a-4e36-b07d-370987e5bf9c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2
		     
	Delayed Healing</title>
                     <text>
                        <paragraph>Topical NSAIDs, including NEVANAC 0.1%, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_3_Corneal_Effects">
                     <id root="05d9aaf7-1a29-46c6-bb17-0b0010f96fd8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3
		     
	Corneal Effects</title>
                     <text>
                        <paragraph>Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including NEVANAC 0.1%, and should be closely monitored for corneal health.</paragraph>
                        <paragraph>Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events, which may become sight threatening. Topical NSAIDs should be used with caution in these patients.</paragraph>
                        <paragraph>Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="01a11820-6769-4e4b-b54f-86f59e673915"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4
		     
	Contact Lens Wear</title>
                     <text>
                        <paragraph>NEVANAC<sup>*</sup> 0.1% should not be administered while using contact lenses.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="0d6c399a-8aad-4be4-b407-68062955ba40"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6</content>
                  <content styleCode="bold">
		     
	ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Increased Bleeding Time <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>
                        <br/>
                     </item>
                     <item>Delayed Healing <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>
                        <br/>
                     </item>
                     <item>Corneal Effects <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20190131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (5% to 10%) are capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure (IOP) and sticky sensation. (<linkHtml href="#_6_1_Clinical_Studies_Experience">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or <linkHtml href="www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1_Clinical_Studies_Experience">
                     <id root="c9b0ed41-b489-4f25-bc24-7817cc64bd88"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1
		     
	Clinical Studies Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The most frequently reported ocular adverse reactions following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure (IOP), and sticky sensation. These reactions occurred in approximately 5% to 10% of patients.</paragraph>
                        <paragraph>Other ocular adverse reactions occurring at an incidence of approximately 1% to 5% included conjunctival edema, corneal edema, dry eye, lid margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing, and vitreous detachment.</paragraph>
                        <paragraph>Some of these reactions may be the consequence of the cataract surgical procedure.</paragraph>
                        <paragraph>Non-ocular adverse reactions reported at an incidence of 1% to 4% included headache, hypertension, nausea/vomiting, and sinusitis.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c94eda43-8257-4c59-b40d-bc1ca683a3a1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8</content>
                  <content styleCode="bold">
		     
	USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20190131"/>
               <component>
                  <section>
                     <id root="195bcaf3-8672-4656-b82d-772f66948c36"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>8.1
		     
	Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Teratogenic Effects</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Pregnancy Category C: </content>Reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of teratogenicity due to nepafenac, despite the induction of maternal toxicity. At this dose, the animal plasma exposure to nepafenac and amfenac was approximately 260 and 2400 times human plasma exposure at the recommended human topical ophthalmic dose for rats and 80 and 680 times human plasma exposure for rabbits, respectively. In rats, maternally toxic doses greater than or equal to 10 mg/kg were associated with dystocia, increased post-implantation loss, reduced fetal weights and growth, and reduced fetal survival. </paragraph>
                        <paragraph>Nepafenac has been shown to cross the placental barrier in rats. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, NEVANAC 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Non-teratogenic Effects</content>
                        </paragraph>
                        <paragraph>Because of the known effects of prostaglandin biosynthesis inhibiting drugs on the fetal cardiovascular system (closure of the ductus arteriosus), the use of NEVANAC 0.1% during late pregnancy should be avoided.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e17acd65-804c-4620-b88f-59bf98aacdf3"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34080-2" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3
		     
	Nursing Mothers</title>
                     <text>
                        <paragraph>Nepafenac is excreted in the milk of lactating rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when NEVANAC 0.1% ophthalmic suspension is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2ce4e915-217e-4989-a252-daabc1397941"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4
		     
	Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of NEVANAC 0.1% in pediatric patients below the age of 10 years have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="cf6023f5-d062-4c36-b89a-2af05c21bf44"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5
		     
	Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety and effectiveness have been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20170622"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="9af87264-5cd9-4471-8373-a3637076b058"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11</content>
                  <content styleCode="bold">
		     
	DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>NEVANAC<sup>*</sup> 0.1% is a sterile, topical NSAID prodrug for ophthalmic use. Each mL of NEVANAC 0.1% contains 3 mg of nepafenac. Nepafenac is designated chemically as 2-amino-3-benzoylbenzeneacetamide with an empirical formula of C15H14N2O2. The structural formula of nepafenac is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000001"/>
                  </paragraph>
                  <paragraph>Nepafenac is a yellow crystalline powder. The molecular weight of nepafenac is 254.28 g/mol. NEVANAC, 0.1% is supplied as a sterile, aqueous suspension with a pH approximately of 7.4. </paragraph>
                  <paragraph>The osmolality of NEVANAC 0.1% is approximately 305 mOsm/kg.</paragraph>
                  <paragraph>Each mL of NEVANAC 0.1% contains: <content styleCode="bold">Active:</content> nepafenac 0.1%. <content styleCode="bold">Inactives:</content> boric acid, propylene glycol, carbomer 974P, sodium chloride, tyloxapol, edetate disodium, benzalkonium chloride 0.005% (preservative), sodium hydroxide and/or hydrochloric acid to adjust pH, and purified water, USP.</paragraph>
               </text>
               <effectiveTime value="20190131"/>
               <component>
                  <observationMedia ID="MM03000001">
                     <text>The structural formula for nepafenac is NEVANAC * (nepafenac ophthalmic suspension), 0.1% is a sterile, topical NSAID prodrug for ophthalmic use. Each mL of NEVANAC (nepafenac ophthalmic suspension), 0.1% contains 3 mg of nepafenac. Nepafenac is designated chemically as 2-amino-3-benzoylbenzeneacetamide with an empirical formula of C15H14N2O2. </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="nevanac-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="382d1f05-eaee-4eee-acf3-32b9ffc66196"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12</content>
                  <content styleCode="bold">
		     
	CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20190131"/>
               <component>
                  <section>
                     <id root="e31d1383-ac83-47a9-965a-fb689e2f9d26"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1
		     
	Mechanism of Action</title>
                     <text>
                        <paragraph>After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, an NSAID. Amfenac is thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.</paragraph>
                     </text>
                     <effectiveTime value="20170622"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2d9abca7-139b-4530-980d-5d1ad3b06511"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3
		     
	Pharmacokinetics</title>
                     <text>
                        <paragraph>Low but quantifiable plasma concentrations of nepafenac and amfenac were observed in the majority of subjects 2 and 3 hours post dose, respectively, following bilateral topical ocular 3 times-daily dosing of nepafenac ophthalmic suspension, 0.1%. The mean steady-state C<sub>max</sub> for nepafenac and for amfenac were 0.310 ± 0.104 ng/mL and 0.422 ± 0.121 ng/mL, respectively, following ocular administration.</paragraph>
                        <paragraph>Nepafenac at concentrations up to 300 ng/mL did not inhibit the in vitro metabolism of 6 specific marker substrates of cytochrome P450 (CYP) isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4). Therefore, drug-drug interactions involving CYP-mediated metabolism of concomitantly administered drugs are unlikely. Drug-drug interactions mediated by protein binding are also unlikely.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="4e000da1-a2ac-4986-82d2-857b42bbff8d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13</content>
                  <content styleCode="bold">
		     
	NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20190131"/>
               <component>
                  <section>
                     <id root="404b5bea-0c98-438d-a35a-9f8c8278a1e3"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1
		     
	Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>Nepafenac has not been evaluated in long-term carcinogenicity studies. Increased chromosomal aberrations were observed in Chinese hamster ovary cells exposed in vitro to nepafenac suspension. Nepafenac was not mutagenic in the Ames assay or in the mouse lymphoma forward mutation assay. Oral doses up to 5000 mg/kg did not result in an increase in the formation of micronucleated polychromatic erythrocytes <content styleCode="italics">in vivo </content>in the mouse micronucleus assay in the bone marrow of mice.</paragraph>
                        <paragraph>Nepafenac did not impair fertility when administered orally to male and female rats at 3 mg/kg (approximately 90 and 380 times the plasma exposure to the parent drug, nepafenac, and the active metabolite, amfenac, respectively, at the recommended human topical ophthalmic dose).</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="736bb8cb-d089-4113-8fee-64df30169192"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14</content>
                  <content styleCode="bold">
		     
	CLINICAL STUDIES</content>
               </title>
               <text>
                  <paragraph>In two double-masked, randomized clinical trials in which patients were dosed 3 times-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and for the first 2 weeks of the postoperative period, NEVANAC 0.1% demonstrated superior clinical efficacy compared to its vehicle in treating postoperative pain and inflammation.</paragraph>
                  <paragraph>Patients treated with NEVANAC<sup>*</sup> 0.1% were less likely to have ocular pain and measurable signs of inflammation (cells and flare) in the early postoperative period through the end of treatment than those treated with its vehicle.</paragraph>
                  <paragraph>For ocular pain in both studies, a significantly higher percentage of patients (approximately 80%) in the nepafenac group reported no ocular pain on the day following cataract surgery (Day 1) compared to those in the vehicle group (approximately 50%).</paragraph>
                  <paragraph>Results from clinical studies indicated that NEVANAC 0.1% has no significant effect upon IOP; however, changes in IOP may occur following cataract surgery.</paragraph>
               </text>
               <effectiveTime value="20190131"/>
            </section>
         </component>
         <component>
            <section>
               <id root="3558b521-d2c8-4939-94e0-68efa9e0e3d0"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16</content>
                  <content styleCode="bold">
		     
	HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>NEVANAC 0.1% is supplied in a white, oval, low density polyethylene DROP-TAINER<sup>®</sup> dispenser with a natural low density polyethylene dispensing plug and gray polypropylene cap. The 1.7 mL fill is presented in an overwrap, which provides tamper evidence to the package. Tamper evidence for the 3 mL fill is provided with a shrink band around the closure and neck area of the package.</paragraph>
                  <paragraph>3 mL in a 4 mL bottle……………………………………………………………………………..NDC 0065-0002-03</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage: </content>Store at 2°C to 25°C (36°F-77°F).</paragraph>
               </text>
               <effectiveTime value="20190131"/>
            </section>
         </component>
         <component>
            <section>
               <id root="f0f9f13d-4c9f-4533-860a-3a9d1145b826"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17</content>
                  <content styleCode="bold">
		     
	PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Slow or Delayed Healing</content>
                  </paragraph>
                  <paragraph>Advise the patient of the possibility that slow or delayed healing may occur while using NSAIDs <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Avoiding Contamination of the Product</content>
                  </paragraph>
                  <paragraph>Advise the patient to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections.  Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.</paragraph>
                  <paragraph>Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Contact Lens Wear</content>
                  </paragraph>
                  <paragraph>Advise the patient that NEVANAC 0.1% should not be administered while wearing contact lens <content styleCode="italics">[see Warnings and Precautions (5.4)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Intercurrent Ocular Conditions</content>
                  </paragraph>
                  <paragraph>Advise the patient that if they develop an intercurrent ocular condition (e.g., trauma, or infection) or have ocular surgery, they should immediately seek their physician’s advice concerning the continued use of the multi-dose container <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Concomitant Topical Ocular Therapy</content>
                  </paragraph>
                  <paragraph>If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart <content styleCode="italics">[see Dosage and Administration (2.2)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Shake Well Before Use</content>
                  </paragraph>
                  <paragraph>Advise the patient to shake the container well <content styleCode="italics">[see Dosage and Administration (2.1)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">ALCON<sup>®</sup>
                     </content>
                     <br/>a Novartis Company
						</paragraph>
                  <paragraph>Distributed by:<br/>Alcon Laboratories, Inc.<br/>Fort Worth, Texas 76134 USA</paragraph>
                  <paragraph>©2007, 2008, 2011, 2017, 2019 Novartis</paragraph>
                  <paragraph>*a trademark of Novartis</paragraph>
                  <paragraph>T2019-22</paragraph>
               </text>
               <effectiveTime value="20190131"/>
            </section>
         </component>
         <component>
            <section>
               <id root="0c4a3ab5-9167-42ab-90dd-460f25b7c0ed"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                     <br/>NDC 0065-0002-03<br/>STERILE<br/>Nevanac<sup>®</sup>
                     <br/>(nepafenac ophthalmic <br/>suspension) 0.1%<br/>3 mL<br/>Alcon<sup>®</sup>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000002"/>
                  </paragraph>
               </text>
               <effectiveTime value="20181218"/>
               <component>
                  <observationMedia ID="MM03000002">
                     <text>PRINCIPAL DISPLAY PANEL
NDC 0065-0002-03
STERILE
Nevanac
(nepafenac ophthalmic 
suspension) 0.1%
3 mL
Alcon
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="nevanac-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>